CA3205777A1 - Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia - Google Patents

Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia

Info

Publication number
CA3205777A1
CA3205777A1 CA3205777A CA3205777A CA3205777A1 CA 3205777 A1 CA3205777 A1 CA 3205777A1 CA 3205777 A CA3205777 A CA 3205777A CA 3205777 A CA3205777 A CA 3205777A CA 3205777 A1 CA3205777 A1 CA 3205777A1
Authority
CA
Canada
Prior art keywords
formula
compound
composition according
pharmaceutical composition
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205777A
Other languages
English (en)
Inventor
Kimberly Vanover
Peng Li
Sharon Mates
Robert Davis
Lawrence P. Wennogle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53274093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3205777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CA3205777A1 publication Critical patent/CA3205777A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3205777A 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia Pending CA3205777A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361911416P 2013-12-03 2013-12-03
US61/911,416 2013-12-03
US201461925607P 2014-01-09 2014-01-09
US61/925,607 2014-01-09
US201461975702P 2014-04-04 2014-04-04
US61/975,702 2014-04-04
US201462032326P 2014-08-01 2014-08-01
US62/032,326 2014-08-01
CA3148326A CA3148326A1 (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3148326A Division CA3148326A1 (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia

Publications (1)

Publication Number Publication Date
CA3205777A1 true CA3205777A1 (en) 2015-06-11

Family

ID=53274093

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2932610A Active CA2932610C (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
CA3148303A Active CA3148303C (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA3148326A Pending CA3148326A1 (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
CA3205777A Pending CA3205777A1 (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CA2932610A Active CA2932610C (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
CA3148303A Active CA3148303C (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA3148326A Pending CA3148326A1 (en) 2013-12-03 2014-12-03 Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia

Country Status (17)

Country Link
US (8) US9956227B2 (enExample)
EP (2) EP3076967B1 (enExample)
JP (5) JP6475727B2 (enExample)
KR (8) KR102373288B1 (enExample)
CN (2) CN105939712A (enExample)
AU (4) AU2014360452C1 (enExample)
BR (1) BR112016012781A2 (enExample)
CA (4) CA2932610C (enExample)
DK (1) DK3076967T3 (enExample)
ES (1) ES2893621T3 (enExample)
HU (1) HUE056496T2 (enExample)
IL (4) IL293523B2 (enExample)
MX (3) MX383855B (enExample)
PL (1) PL3076967T3 (enExample)
PT (1) PT3076967T (enExample)
RU (1) RU2682658C1 (enExample)
WO (1) WO2015085004A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4072553A4 (en) * 2019-12-13 2023-11-22 Halo Science LLC Cariprazine release formulations

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5567349B2 (ja) 2007-03-12 2014-08-06 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリンの合成
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
CN105168219B (zh) * 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
DK2364142T3 (en) 2008-10-28 2018-04-30 Arena Pharm Inc COMPOSITIONS OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USED FOR TREATMENT OF DISEASES RELATED TO THE RECEPTOR
US8653263B2 (en) 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
ES2602503T3 (es) 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US11053245B2 (en) 2012-04-14 2021-07-06 Intra-Cellular Therapies, Inc. Methods
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
BR112016023162B1 (pt) 2014-04-04 2022-11-29 Intra-Cellular Therapies, Inc Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
PT3261645T (pt) 2015-02-27 2021-06-17 Dechra Ltd Estimulação do apetite, gestão da perda de peso, e tratamento da anorexia em cães e gatos
WO2017011767A2 (en) * 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
CN105560192A (zh) * 2016-01-07 2016-05-11 万全万特制药江苏有限公司 一种棕榈酸帕利哌酮长效微球注射液的制备方法
IL296884B2 (en) 2016-01-26 2024-05-01 Intra Cellular Therapies Inc Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders
PH12018501903B1 (en) 2016-03-10 2023-03-17 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
PL3407889T3 (pl) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
JP6997718B2 (ja) * 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
JP2019510039A (ja) * 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
CN116327770B (zh) * 2017-03-24 2025-10-31 细胞内治疗公司 新组合物和方法
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
AU2018307480B2 (en) 2017-07-26 2023-11-23 Intra-Cellular Therapies, Inc. Organic compounds
CA3071119A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment or prophylaxis of central nervous system disorders
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
CN118955352A (zh) 2017-12-05 2024-11-15 赛诺维信制药公司 晶体形式及其制备方法
MY204380A (en) 2017-12-05 2024-08-27 Sunovion Pharmaceuticals Inc Nonracemic mixtures and uses thereof
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
CA3094949A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Deuterated heterocycle fused gamma-carbolines
CA3102848A1 (en) 2018-06-06 2019-12-12 Intra-Cellular Therapies, Inc. Novel salts and crystals
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
AU2019287460B2 (en) 2018-06-11 2024-02-15 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
JP7502199B2 (ja) 2018-06-20 2024-06-18 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
EP3811371A1 (en) 2018-06-21 2021-04-28 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019331490B2 (en) 2018-08-31 2025-04-24 Intra-Cellular Therapies, Inc. Novel methods
MX2021002322A (es) * 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
CA3110997A1 (en) 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
EP3898221A4 (en) 2018-12-17 2022-09-14 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
WO2020131911A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
EP3897621A4 (en) 2018-12-21 2022-09-07 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
KR20200087594A (ko) 2019-01-11 2020-07-21 한국화학연구원 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
KR20220018004A (ko) 2019-06-04 2022-02-14 선오비온 파마슈티컬스 인코포레이티드 조절 방출 제형 및 이의 용도
CA3141223A1 (en) 2019-07-07 2021-01-14 Sharon Mates Novel methods
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
IL292487A (en) 2019-11-01 2022-06-01 Aquestive Therapeutics Inc Prodrug compositions and methods of treatment
CN115038451A (zh) 2019-11-14 2022-09-09 阿奎斯蒂弗医疗股份有限公司 多模式组合物和治疗方法
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
WO2021127572A1 (en) * 2019-12-19 2021-06-24 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
KR102383448B1 (ko) 2020-04-20 2022-04-06 한국화학연구원 락트산 또는 글리콜산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
CN116940351A (zh) 2021-01-15 2023-10-24 阿奎斯蒂弗医疗股份有限公司 前药组合物和治疗方法
AU2022226584A1 (en) 2021-02-24 2023-08-17 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
WO2022192476A1 (en) 2021-03-09 2022-09-15 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
US20250091990A1 (en) * 2022-01-03 2025-03-20 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
JP2025521115A (ja) 2022-05-18 2025-07-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
WO2025010266A1 (en) 2023-07-02 2025-01-09 Engrail Therapeutics, Inc. Deuterated organic compounds and uses thereof
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) * 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
EP0238059B1 (en) 1986-03-19 1993-06-16 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same
ATE91129T1 (de) 1986-04-07 1993-07-15 Kumiai Chemical Industry Co 5h-1,3,4-thiadiazolo(3,2-a>pyrimidin-5-onderivate und diese enthaltende gartenbau- und landwirtschaftliche fungizidmittel.
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
JP3645906B2 (ja) * 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された３−ピペリジニル−置換１，２−ベンズイソオキサゾール類及び１，２−ベンズイソチアゾール類
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
WO1999018057A1 (en) 1997-10-06 1999-04-15 Massachusetts Institute Of Technology Preparation of diaryl ether by condensation reactions
JP4647780B2 (ja) 1998-02-26 2011-03-09 マサチューセッツ インスティテュート オブ テクノロジー ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DK1097158T3 (da) 1998-07-10 2006-05-29 Massachusetts Inst Technology Ligander til metaller og metalkatalyserede metoder
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
EP1140012B1 (en) 1998-12-17 2004-03-03 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
NO309305B1 (no) 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
AU5615900A (en) 1999-06-15 2001-01-02 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6699852B2 (en) 2000-12-20 2004-03-02 Bristol-Myers Squibb Pharma Company Substituted pyridoindoles as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
JP5291854B2 (ja) 2001-04-24 2013-09-18 マサチューセッツ インスチテュート オブ テクノロジー 炭素−ヘテロ原子間及び炭素−炭素間結合の銅を触媒とした形成
DE10123129A1 (de) 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE60206636T2 (de) 2001-08-08 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo THERAPEUTISCHE 1H-PYRIDO[4,3-b]INDOLE
EP1314554A1 (fr) 2001-11-23 2003-05-28 Kba-Giori S.A. Dispositif de décollage d'éléments de sécurité
DE10162121A1 (de) 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
RU2321391C2 (ru) 2002-07-29 2008-04-10 Алза Корпорейшн Способы и лекарственные формы для контролируемой доставки палиперидона
CA2494404A1 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
AU2003287433A1 (en) 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
EP1581221B1 (en) 2002-12-19 2011-05-18 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
ES2367135T3 (es) 2003-01-16 2011-10-28 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.
KR20060037391A (ko) 2003-07-21 2006-05-03 스미스클라인 비참 코포레이션 (2Ｓ,4Ｓ)-4-플루오로-1-[4-플루오로-베타-(4-플루오로페닐)-Ｌ-페닐알라닐]-2-피롤리딘카르보니트릴 ｐ-톨루엔설폰산염 및 이의 무수 결정 형태
AR045796A1 (es) 2003-09-26 2005-11-16 Solvay Pharm Bv Derivados de hexa y octahidro - pirido (1,2-a) pirazina con actividad antagonista de nk1. composiciones farmaceuticas.
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US20080280941A1 (en) 2004-03-05 2008-11-13 Pierre Lourtie 8-Phenoxy-Gamma Carboline Derivatives
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
ATE506945T1 (de) 2004-09-20 2011-05-15 Sinai School Medicine Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
JP2008513432A (ja) 2004-09-21 2008-05-01 ファイザー・プロダクツ・インク Ｃｎｓ状態の治療に有用なｎ−メチルヒドロキシエチルアミン
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
CN100586951C (zh) 2004-12-15 2010-02-03 弗·哈夫曼-拉罗切有限公司 作为甘氨酸转运体l(GlyT-1)抑制剂用于治疗阿尔茨海默氏病的二环和三环取代的苯甲酮化合物
NZ556761A (en) * 2005-01-25 2011-04-29 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
AR052196A1 (es) 2005-01-25 2007-03-07 Celgene Corp Metodos y composiciones que utilizan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona
WO2006123359A2 (en) * 2005-03-01 2006-11-23 Sun Pharmaceutical Industries Limited A process of making microspheres
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2007084841A2 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
JP5567349B2 (ja) 2007-03-12 2014-08-06 イントラ−セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ−カルボリンの合成
BRPI0815850A2 (pt) 2007-08-01 2014-10-07 Medivation Neurology Inc "método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico"
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US20090209608A1 (en) 2007-08-29 2009-08-20 Protia, Llc Deuterium-enriched asenapine
US20090076159A1 (en) 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched eplivanserin
AU2009212065B2 (en) 2008-02-05 2014-03-20 Clera Inc. Compositions and methods for alleviating depression or improving cognition
CN101986784A (zh) 2008-02-07 2011-03-16 先灵公司 基因工程tslpr抗体
ES2530090T3 (es) * 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CN105168219B (zh) * 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
WO2010037142A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
WO2010104819A2 (en) * 2009-03-09 2010-09-16 Board Of Regents, The University Of Texas System Hollow gold nanospheres (haunss) and haunss-loaded microspheres useful in drug delivery
ES2602503T3 (es) * 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. Compuestos orgánicos
WO2012083269A1 (en) 2010-12-16 2012-06-21 Cynapsus Therapeutics, Inc. Sublingual films
US11053245B2 (en) 2012-04-14 2021-07-06 Intra-Cellular Therapies, Inc. Methods
RU2015113558A (ru) 2012-09-14 2016-11-10 Эббви Дойчланд Гмбх Унд Ко. Кг Трициклические хинолиновые и хиноксалиновые производные
PL2968320T3 (pl) * 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
BR112016023162B1 (pt) * 2014-04-04 2022-11-29 Intra-Cellular Therapies, Inc Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
IL296884B2 (en) 2016-01-26 2024-05-01 Intra Cellular Therapies Inc Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders
US20200392135A1 (en) * 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
PL3407889T3 (pl) * 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
JP6997718B2 (ja) * 2016-03-28 2022-01-18 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規共結晶
WO2018106916A1 (en) 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
CN116327770B (zh) * 2017-03-24 2025-10-31 细胞内治疗公司 新组合物和方法
US11655251B2 (en) 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
EP3746081A4 (en) * 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
EP3765021A4 (en) * 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
IL303857B2 (en) * 2018-03-23 2024-08-01 Intra Cellular Therapies Inc organic compounds
US12144808B2 (en) * 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
EP4034119A4 (en) * 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
JP2025521115A (ja) * 2022-05-18 2025-07-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4072553A4 (en) * 2019-12-13 2023-11-22 Halo Science LLC Cariprazine release formulations

Also Published As

Publication number Publication date
US20240024334A1 (en) 2024-01-25
JP2025032193A (ja) 2025-03-11
AU2020202386A1 (en) 2020-04-30
KR20240119197A (ko) 2024-08-06
US9956227B2 (en) 2018-05-01
IL246002B2 (en) 2024-11-01
US20180200256A1 (en) 2018-07-19
IL246002A0 (en) 2016-07-31
IL321987A (en) 2025-09-01
AU2021290277B2 (en) 2023-07-20
US20160310502A1 (en) 2016-10-27
KR20210049199A (ko) 2021-05-04
AU2020202386B2 (en) 2021-09-30
IL305990A (en) 2023-11-01
CA2932610A1 (en) 2015-06-11
CA2932610C (en) 2023-08-22
CA3148303A1 (en) 2015-06-11
JP2016539144A (ja) 2016-12-15
US10960009B2 (en) 2021-03-30
PL3076967T3 (pl) 2021-12-20
WO2015085004A1 (en) 2015-06-11
AU2021290277A1 (en) 2022-01-27
JP2021075566A (ja) 2021-05-20
US20250360140A1 (en) 2025-11-27
CA3148303C (en) 2024-02-27
US20210322433A1 (en) 2021-10-21
AU2014360452C1 (en) 2019-05-16
ES2893621T3 (es) 2022-02-09
AU2014360452A1 (en) 2016-07-21
KR102495941B1 (ko) 2023-02-06
US11026951B2 (en) 2021-06-08
MX395458B (es) 2025-03-25
CN114366741A (zh) 2022-04-19
KR20230058736A (ko) 2023-05-03
JP7600299B2 (ja) 2024-12-16
KR20210049200A (ko) 2021-05-04
CN105939712A (zh) 2016-09-14
KR102287288B1 (ko) 2021-08-06
AU2019200301B2 (en) 2020-01-30
AU2014360452B2 (en) 2018-10-18
BR112016012781A2 (pt) 2017-08-08
MX2021007665A (es) 2022-09-09
MX2016007219A (es) 2016-09-16
JP6874028B2 (ja) 2021-05-19
JP2023089113A (ja) 2023-06-27
AU2019200301A1 (en) 2019-02-07
MX2022011140A (es) 2022-10-13
KR20160093055A (ko) 2016-08-05
EP3666271A1 (en) 2020-06-17
KR102692169B1 (ko) 2024-08-05
HUE056496T2 (hu) 2022-02-28
KR102421656B1 (ko) 2022-07-15
IL293523B1 (en) 2023-10-01
IL246002B (en) 2022-07-01
EP3076967A1 (en) 2016-10-12
DK3076967T3 (da) 2021-10-25
KR20210101326A (ko) 2021-08-18
KR102372145B1 (ko) 2022-03-07
US10322134B2 (en) 2019-06-18
CA3148326A1 (en) 2015-06-11
KR20230023817A (ko) 2023-02-17
IL305990B2 (en) 2025-12-01
JP6475727B2 (ja) 2019-02-27
KR102373288B1 (ko) 2022-03-10
AU2020202386C1 (en) 2022-04-07
JP7262495B2 (ja) 2023-04-21
EP3076967B1 (en) 2021-07-28
IL293523B2 (en) 2024-02-01
KR20220103822A (ko) 2022-07-22
RU2682658C1 (ru) 2019-03-20
EP3076967A4 (en) 2017-05-10
US20190290655A1 (en) 2019-09-26
US20190328745A1 (en) 2019-10-31
US10960010B2 (en) 2021-03-30
PT3076967T (pt) 2021-10-07
IL305990B1 (en) 2025-08-01
JP2019077724A (ja) 2019-05-23
US20190298730A1 (en) 2019-10-03
IL293523A (en) 2022-08-01
MX383855B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
AU2021290277B2 (en) Novel methods
HK40032048A (en) Miscrospheres comprising a plga matrix for medical use
HK1228774B (en) Methods for treating residual symptoms of schizophrenia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230707

EEER Examination request

Effective date: 20230707

EEER Examination request

Effective date: 20230707

EEER Examination request

Effective date: 20230707